<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881582</url>
  </required_header>
  <id_info>
    <org_study_id>RMH-01-09</org_study_id>
    <nct_id>NCT00881582</nct_id>
  </id_info>
  <brief_title>Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients</brief_title>
  <official_title>Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Abdulaziz Medical City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Riyadh Military Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King Faisal Specialist Hospital &amp; Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King Abdulaziz Medical City</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a distinct lack of published literature on the effect of combination treatment of&#xD;
      PEG-interferon and ribavirin on post-renal transplantation hepatitis C virus (HCV) patients.&#xD;
      Small case series have been published utilizing conventional interferon and/or ribavirin and&#xD;
      the available data is extremely preliminary in nature. A small retrospective series of&#xD;
      patients treated with Pegylated interferon and ribavirin published recently suggests that the&#xD;
      treatment may be safe and efficacious. Unpublished reports from a few centers within Saudi&#xD;
      Arabia also suggest a good safety profile and reasonable efficacy from this form of&#xD;
      combination treatment.&#xD;
&#xD;
      The investigators aim to prospectively study the safety and efficacy of PEG-interferon and&#xD;
      ribavirin combination therapy in post-renal transplant HCV-infected patients. Towards this 40&#xD;
      patients with histological evidence of liver disease will be recruited and the efficacy of&#xD;
      the above medications studied.&#xD;
&#xD;
      The proposed study aims to evaluate the efficacy and safety of PEG-interferon and ribavirin&#xD;
      combination therapy in the treatment of chronic HCV in renal transplant patients in a way&#xD;
      that will allow management of such patients in an optimized manner.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response</measure>
    <time_frame>At 24 weeks post completion of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate and number of cases of graft rejection</measure>
    <time_frame>Assessment at 4, 12, 24 and 48 weeks on treatment, and 24 weeks post completion of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Renal Transplant</condition>
  <arm_group>
    <arm_group_label>Pegylated interferon alfa-2a plus ribavarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated interferon alfa-2a plus ribavarin for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a plus ribavarin</intervention_name>
    <description>PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 &amp; 4: 48 weeks; genotypes 2 &amp; 3: 24 weeks)</description>
    <arm_group_label>Pegylated interferon alfa-2a plus ribavarin</arm_group_label>
    <other_name>Pegasys®, F. Hoffman-LaRoche</other_name>
    <other_name>Copegus®, F. Hoffman-LaRoche</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients, male and female, aged 18 - 68 years&#xD;
&#xD;
          -  Post renal transplant patients exceeding one year&#xD;
&#xD;
          -  Anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic, Chicago, IL) positive &gt; 6 months&#xD;
             AND/OR&#xD;
&#xD;
          -  Detectable serum quantitative HCV-RNA (Cobas Amplicor HCV Monitor v2.0, Roche&#xD;
             Molecular Systems, Pleasanton, CA) with lower limit of detection at 50 IU/mL&#xD;
&#xD;
          -  Compensated liver disease with the following minimum hematologic and biochemical&#xD;
             criteria:&#xD;
&#xD;
          -  Hemoglobin &gt; 10 g/dL&#xD;
&#xD;
          -  WBC &gt; 3000/mm3 ; granulocyte count &gt; 1,500/mm3&#xD;
&#xD;
          -  Platelet count &gt; 75,000/mm3&#xD;
&#xD;
          -  Albumin within normal limits&#xD;
&#xD;
          -  TFT within normal limits&#xD;
&#xD;
          -  ANA &lt; 1:320&#xD;
&#xD;
          -  Ultrasound of the liver obtained within the preceding 6 months of study entry&#xD;
&#xD;
          -  Liver biopsy prior to entry confirming a histological diagnosis consistent with HCV&#xD;
             necroinflammatory score (METAVIR) &gt; 1, and fibrosis score &gt;/= 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with interferon and / or Ribavirin - based therapy for chronic&#xD;
             hepatitis C&#xD;
&#xD;
          -  Co-infection with HBV or HIV&#xD;
&#xD;
          -  Chronic alcohol abuse (daily consumption &gt; 20 g/day)&#xD;
&#xD;
          -  Autoimmune or metabolic liver disease liver disease&#xD;
&#xD;
          -  Active drug-induced hepatitis or HAV&#xD;
&#xD;
          -  Decompensated liver disease (Child-Pugh classification B or C) including a past&#xD;
             history of decompensation&#xD;
&#xD;
          -  Variceal bleeding&#xD;
&#xD;
          -  Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration) or clinically&#xD;
             relevant ophthalmological disorder due to diabetes mellitis or hypertension&#xD;
&#xD;
          -  Neoplastic disease&#xD;
&#xD;
          -  Patients with a value of alpha-fetoprotein &gt;100 ng/mL will be excluded from the study&#xD;
             until imaging studies confirm the absence of HCC. Presence of HCC, as determined by&#xD;
             other means will also exclude the patient from histological sampling.&#xD;
&#xD;
          -  Patients with documented or presumed coronary artery disease or cerebrovascular&#xD;
             disease should not be enrolled if, in the judgment of the investigator, an acute&#xD;
             decrease in hemoglobin by up to 4 g/dL (40 g/L) (as may be seen with ribavirin&#xD;
             therapy) would not be well-tolerated&#xD;
&#xD;
          -  History of severe psychiatric disease, especially depression. Severe psychiatric&#xD;
             disease is defined as treatment with an antidepressant medication or a major&#xD;
             tranquilizer at therapeutic doses for major depression or psychosis, respectively, for&#xD;
             at least 3 months at any previous time or any history of the following: a suicidal&#xD;
             attempt, hospitalization for psychiatric disease, or a period of disability due to a&#xD;
             psychiatric disease&#xD;
&#xD;
          -  Evidence of drug abuse (including excessive alcohol consumption) within one year of&#xD;
             study entry&#xD;
&#xD;
          -  Current pregnancy, ongoing breast feeding or unwilling to have contraception&#xD;
&#xD;
          -  Bleeding or clotting diatheses&#xD;
&#xD;
          -  Recent history of renal allograft rejection (&lt; 6 months)&#xD;
&#xD;
          -  Inability or unwillingness to provide informed consent or abide by the requirements of&#xD;
             the study.&#xD;
&#xD;
          -  History or other evidence of severe illness or any other conditions which would make&#xD;
             the patient, in the opinion of the investigator, unsuitable for the study.&#xD;
&#xD;
          -  History of organ transplantation, other than kidney, with an existing functional&#xD;
             graft.&#xD;
&#xD;
          -  Patients requiring dialysis or in whom dialysis is impending.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faisal M Sanai, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Riyadh Military Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital &amp; Research Centre</name>
      <address>
        <city>Riyadh</city>
        <zip>11159</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riyadh Military Hospital</name>
      <address>
        <city>Riyadh</city>
        <zip>11159</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>April 14, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Abdulaziz Medical City</investigator_affiliation>
    <investigator_full_name>Faisal M Sanai</investigator_full_name>
    <investigator_title>Consultant Hepatologist &amp; Liver Transplant Physician</investigator_title>
  </responsible_party>
  <keyword>Hepatitis c</keyword>
  <keyword>Renal transplantation</keyword>
  <keyword>Pegylated interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

